III.—New Developments in Large-scale Plasma Fractionation

1972 ◽  
Vol 71 (S1) ◽  
pp. s15-s34
Author(s):  
J. G. Watt ◽  
J. K. Smith ◽  
W. Grant ◽  
C. Turnbull

‘Selective transfusion of appropriate blood components is preferable to the routine use of whole blood.’ (American Association of Blood Banks. Physicians' Handbook of Blood Component Therapy, 1969).The rational use of donor blood in the environment of modern blood transfusion revolves around a series of developments in the field of component therapy. The fractionation of plasma, i.e. the separation of plasma into a series of subdivisions each containing one or other of the constituent proteins in varying degrees of purity and concentration, was one of the first of these developments to become established.Early fractionation of plasma was applied in various ways to the purification of animal antisera; initially to antipneumococcal serum for therapeutic use. These sera frequently provoked reactions in patients until Sabin showed that absorption with Fullers earth could abolish these side-effects by removing complexed molecules.

2012 ◽  
Vol 65 (1-2) ◽  
pp. 50-53 ◽  
Author(s):  
Jasmina Grujic ◽  
Zdravko Gulan ◽  
Zorana Budakov

Introduction. Application of blood and blood components throughout decades is very successful and mostly safe procedure in patients? therapy. However, it may lead to unfavourable effects, such as transfusion reactions. Material and Methods. In the period from 2000 to 2009, 180 transfusion reactions were reported at the Department of Clinical Transfusion of the Service for Blood Transfusion of Vojvodina in Novi Sad. The aetiology of transfusion reactions was determined by examining pretransfusion and post-transfusion sample of patient?s blood and by examining the unit of blood component that induced reaction. Results. Out of 180 reported transfusion reactions, 98 (54.4%) were febrile non-haemolytic transfusion reactions, 69 (38.3%) allergic reactions and 2 (1.11%) haemolytic reactions. Blood components that caused most of transfusion reactions were erythrocytes (62.4%), fresh frozen plasma (11.2%) and platelets (14.4%). All patients underwent multiple transfusions. Discussion. The fact that only 0.13% transfusion reactions were reported, compared with data from literature (2-15%), points to the lack of regular reporting of transfusion reactions, as well as the fact that there is only one report of delayed transfusion reaction. Conclusions. To improve and make blood transfusion safer it is necessary to respect all pre-transfusion procedures, constant follow up of blood transfusion must be done and patients with diagnosed non-haemolytic transfusion reaction should be given leukocyte reduced blood components.


Author(s):  
Hanane El Kenz ◽  
Philippe Van der Linden

Following the discovery of the ABO blood groups by Landsteiner in 1901, Albert Hustin described the first transfusion of a whole blood unit in 1914. The modern transfusion era really begins in 1916 with the discovery of sodium citrate as an anticoagulant by the same physician, allowing blood conservation in dedicated packs. Since that time, many advances have been made especially over the past two decades in the storage, the conservation, and the laboratory testing of blood components and in transfusion medicine practice. Transfusion of whole blood has been replaced by blood component therapy, which consists of the administration of packed red blood cells, fresh frozen plasma, or platelets. Although blood transfusion is safer than ever, the risk of complications will never reach zero. The risk of infectious transfusion-transmitted diseases has been markedly reduced by the implementation of extensive infectious disease testing, donor selection, and pathogen-inactivation procedures. In countries with a high human development index, the leading causes of allogeneic blood transfusion-related deaths actually resulted from immunological and septic complications. The first section of this chapter describes the structure, function, and immunological aspects of the different blood components that are routinely transfused today. The second section details the composition of the different blood components, their indications, the pre-transfusion compatibility tests, and the main adverse effects associated with their transfusion.


2002 ◽  
Vol 126 (8) ◽  
pp. 909-914 ◽  
Author(s):  
David A. Novis ◽  
Richard C. Friedberg ◽  
Stephen W. Renner ◽  
Frederick A. Meier ◽  
Molly K. Walsh

Abstract Objectives.—To determine the normative distribution of time elapsed for blood bank personnel to fill nonscheduled operating room (OR) blood component orders in hospital communities throughout the United States, and to examine hospital blood bank practices associated with faster blood component delivery times. Design.—Participants in the College of American Pathologists Q-Probes laboratory quality improvement program collected data prospectively on the times elapsed for blood bank personnel to fill nonscheduled emergent orders from hospital ORs for red blood cell (RBC) products, fresh frozen plasma (FFP), and platelets (PLTs). Participants also completed questionnaires describing their hospitals' and blood banks' laboratory and transfusion practices. Setting and Participants.—Four hundred sixty-six public and private institutions located in 48 states in the United States (n = 444), Canada (n = 9), Australia (n = 8), the United Kingdom (n = 4), and Spain (n = 1). Main Outcome Measures.—The median time elapsed between requests for blood components by OR personnel and the retrieval of those components by blood component transport personnel, and the median time elapsed between requests for blood components by OR personnel and the arrival of those components in ORs. Results.—Participants submitted data on 12 647 units of RBCs, FFP, and PLTs. The median aggregate request-to-retrieval turnaround times (TATs) for RBCs, FFP, and PLTs ranged from 30 to 35 minutes, and the median aggregate request-to-arrival TATs for RBCs, FFP, and PLTs ranged from 33 to 39 minutes. Most of the TAT was consumed by events occurring prior to, rather than after release of components from blood banks. Shorter prerelease TATs were associated with having surgical schedules that listed patients' names and procedures available to blood bank personnel prior to surgeries, and having adequate clotted specimens in the blood bank and completed type-and-screen procedures performed before requests for blood components were submitted to blood banks. Among the fastest-performing 10% of participants (90th percentile and above), request-to-retrieval TATs ranged from 12 to 24 minutes for the 3 blood components, whereas among the slowest-performing 10% of participants (10th percentile and below), request-to-retrieval TATs ranged from 63 to 115 minutes for the 3 components. Median TATs ranged from 33 to 37 minutes for the 3 components. Institutions with TATs in the fastest-performing 25th percentile more frequently stored cross-matched RBCs in the OR daily, stocked PLTs for unexpected surgical use, stored PLTs in or near the OR, and had laboratory rather than nonlaboratory personnel deliver components to the OR than did those institutions with TATs in the slowest-performing 25th percentile. Conclusions.—Hospital blood bank personnel can deliver blood components to the OR in slightly longer than 30 minutes, measured from the time that those units are requested by OR personnel. Practices aimed at saving time before components are released from blood banks will be more efficient in reducing overall TAT than those practices aimed at saving time after components are released from blood banks. Specific practices associated with shorter blood delivery TATs included providing blood bank personnel with access to the names of surgical patients potentially requiring blood components, having pretransfusion testing completed on those patients prior to surgery, having ample blood products on hand, and having laboratory personnel control blood product delivery.


2004 ◽  
Vol 128 (3) ◽  
pp. 279-281 ◽  
Author(s):  
Kathleen H. Burns ◽  
Jochewed B. Werch

Abstract The most common transfusion-associated infectious risk in the United States today is bacterial contamination of platelet components. Bacterial contamination is estimated to occur at an incidence of 1:1000 to 1:3000 in platelet units, with severe episodes estimated to occur in about one sixth of contaminated products. Increased awareness and prompt reaction of the medical team can greatly affect the outcome and save a patient's life. The following case history illustrates this issue. A young woman developed chills and rigors while receiving 1 unit of leuko-reduced apheresis platelets for severe thrombocytopenia. The transfusion was stopped, blood cultures were drawn, and the patient developed clinical signs of sepsis. Cultures of both the platelet unit and the patient's blood revealed coagulase-negative Staphylococcus. Microbial susceptibilities in both samples were identical. Pretransfusion blood cultures taken from the patient earlier that day were negative. The platelet unit had been stored for 5 days. We review this case and the literature describing the persistent problem of platelet unit contamination and at the same time highlight the efforts now directed by the American Association of Blood Banks and College of American Pathologists to address this issue. Although there is no uniform approach to dealing with bacterial contamination of platelets, the American Association of Blood Banks and the College of American Pathologists have promulgated new accreditation requirements in an effort to prevent bacterial sepsis associated with platelet transfusion. A new American Association of Blood Banks standard, which will be effective March 1, 2004, requires a combination of strategies both to limit the initial inoculation of bacteria into the blood component and to detect subsequent growth at room temperature (American Association of Blood Banks Association Bulletin #03-12). The new College of American Pathologists Checklist question, which became effective in December 2003, is a Phase 1 requirement that calls for inspected facilities to have a platelet bacteria detection method in place.


2021 ◽  
Vol 15 (10) ◽  
pp. 2593-2594
Author(s):  
Amer Latif ◽  
M. Asim Rana ◽  
Shahzad Ashraf ◽  
M. Afzal Bhatti ◽  
Muhammad Javed ◽  
...  

Background: Liver transplantation is a complicated surgical procedure that involves many complexities such as bleeding and the risk of transfusing blood components. Aim: To investigate the effect of the Rotational Thormboelastometry (ROTEM) algorithm-based blood or blood product transfusion, in clinical outcome of living donor liver transplant (LDLT) patients. Study design: Retrospective study Place and duration of the study: Bahria Town international hospital Lahore from 1st January 2016 to 31st December 2020. Methodology: Sixty patients of living donor liver transplant were enrolled. They were then divided into two groups as per the approved transfusion protocol. The first group named pre-ROTEM and the second was ROTEM group. Initial biochemical features, blood transfusion and patient outcomes were documented. Results: The need for large-scale blood transfusion and transfusion-related products were statistically less in ROTEM group as compared to the pre-ROTEM group. Conclusion: The ROTEM-based algorithms can be used effectively to reduce transfusion of blood components and may increase the chances of early transplant functioning. Keywords: ROTEM algorithm, Blood transfusion, Liver transplant, ASA guideline, Thromboelastogram, TEG


2007 ◽  
Vol 131 (5) ◽  
pp. 690-694
Author(s):  
Melanie A. Osby ◽  
Sunita Saxena ◽  
Janice Nelson ◽  
Ira Shulman

Abstract Context.—The more advanced we become, the more evident are the infectious and noninfectious risks of the blood supply. Infectious risks are somewhat straightforward and are addressed by implementing stricter donor criteria and testing. The noninfectious risks, however, are more complicated. Each step in the transfusion process, beginning with the physician who orders a transfusion to the actual transfusion of the component, is subject to adverse outcomes and increases the noninfectious risks of transfusion. The challenges to provide the safest blood possible with zero risk have resulted in the implementation of stringent standards from both the American Association of Blood Banks and the Joint Commission on Accreditation of Healthcare Organizations. Objective.—A series of case scenarios serve as the basis for discussion of the risks, which affect the safety and administration of blood components, inherent in the transfusion process. Data Sources.—Journals, textbooks, Internet. Conclusions.—The transfusion process is a complex multistep process with inherent risks. Infectious risks of transfusion are being adequately addressed such that the noninfectious risks of transfusion are becoming much more evident. Patient safety can be compromised if each step of the transfusion process is not completed according to established policies and procedures at each individual institution.


2016 ◽  
Vol 2016 ◽  
pp. 1-28 ◽  
Author(s):  
Jason P. Acker ◽  
Denese C. Marks ◽  
William P. Sheffield

Blood is donated either as whole blood, with subsequent component processing, or through the use of apheresis devices that extract one or more components and return the rest of the donation to the donor. Blood component therapy supplanted whole blood transfusion in industrialized countries in the middle of the twentieth century and remains the standard of care for the majority of patients receiving a transfusion. Traditionally, blood has been processed into three main blood products: red blood cell concentrates; platelet concentrates; and transfusable plasma. Ensuring that these products are of high quality and that they deliver their intended benefits to patients throughout their shelf-life is a complex task. Further complexity has been added with the development of products stored under nonstandard conditions or subjected to additional manufacturing steps (e.g., cryopreserved platelets, irradiated red cells, and lyophilized plasma). Here we review established and emerging methodologies for assessing blood product quality and address controversies and uncertainties in this thriving and active field of investigation.


2021 ◽  
Vol 21 (3) ◽  
pp. 1230-1236
Author(s):  
Esther Obi ◽  
Claudius Diette-spiff ◽  
Hannah Omunakwe

Introduction: Comprehension of blood component therapy (BCT) has profound impact on transfusion outcomes. Varia- tions from the standards in practices of BCT may jeopardize patient care. Aim: To assess the understanding and implementation of BCT by physicians. Methods: The study was carried out at two tertiary health care centres. It was a descriptive cross- sectional study using a self-administered, questionnaire comprising of 30 questions. Result: A total of 265 physicians responded from various clinical specialties. Physicians studied showed remarkable knowl- edge (98%) of BCT. Nevertheless, 92.8% of the respondents' were inclined to prescribing whole blood and the common- est reason given was ready availability at the blood bank. More than half of the respondents' have prescribed BCT with sedimented red cells and platelet concentrates being the most frequently prescribed blood components. Non-availability of blood components and cost implications were some of the identified limitations to the use of BCT. Conclusion: Majority of the physicians have a good knowledge concerning BCT. Nonetheless, there was a knowledge-prac- tice mismatch attributable to the unavailability of the various blood components limiting optimal practice of BCT. Strategies should be formulated to overcome these identified challenges to ensure quality transfusion services in our healthcare facil- ities. Keywords: Physicians; blood component therapy; blood transfusion; blood components; knowledge.


Sign in / Sign up

Export Citation Format

Share Document